Results with Lifescozul™Prostate Cancer
Introduction to the case
Mr. Eberto is a Colombian gentleman who in his way of being represents everything that is good about Colombians. He is kind, he is genuine in his friendship and for everything he is a smile. As we say, he is a beautiful person.
People like that don't give up, they fight through everything with a big smile and are an inspiration for our day. I have the pleasure of meeting him, his wife and daughter, and even greater pleasure to be able to tell their story of success with our treatment.
Eberto Gómez, Male, 66 years old at the beginning of treatment with LifEscozul.
Loss of weight and muscle mass, depression, nervousness, weakness.
July 8, 2017.
Ca prostate (poorly differentiated acinar adenocarcinoma) (Gleason 4+3=7) with neuroendocrine differentiation, stage IV due to multiple bone metastases and multiple retroperitoneal, right inguinal, paravesical, right paraprostatic, mediastinal and supraclavicular adenopathy.
Eberto was diagnosed with aggressive stage IV prostate cancer in June 2017. The prognosis for life unfortunately for this type of cancer and stage is not good.
Mr. Eberto received hormone therapy treatment with Bicalutamide and Decapeptil as part of his conventional treatments. He also received, additionally radiotherapy on lumbar spine in July 2017.
However, none of this was able to control his cancer and his PSA (prostate antigen) values when starting LifEscozul (escozul, blue scorpion venom) were 2000 ng/ml with the average reference value being 4 ng/ml.
His physical condition showed marked deterioration with weight loss and depression.
However, for us with regard to prostate cancer, we know that we can obtain good results, because out of 300 people treated at different stages, 80% had a favorable response.
The dose design took into account these previous experiences and Mr. Eberto was administered a high dose from the beginning seeking to reduce as a primary objective the PSA value and in parallel improve his quality of life. With these two objectives outlined, Mr. Eberto started LifEscozul in July 2017.
As with all our cases, Mr. Eberto was assigned a personalized physician as well as a scientific advisor.
Evolution with LifEscozul™ and actual results
Mr. Eberto's family, first his brother and then his daughter, have been in close contact with our medical team during the whole treatment period, allowing us to observe his evolution in real time.
By August 2017 the family refers us that the prostate antigen had decreased to 69 ng/ml. All this in just one month we had managed to go from 2000 to 69 ng/ml.
We were further informed that Mr. Eberto was eating better and had regained weight and was in good spirits with an optimistic attitude.
However by January 2018 we received a PET-CT report indicating presence of adenomegaly in pelvic wall and nodular lesion in surgical bed of 13x9mm.
In addition to blast lesions scattered throughout the skeletal system in 4th and 7th left costal arches, C4, C7, T1, T4, T11, L5, left iliac and sacral wings, left acetabulum, proximal third of right femur.
The medical team of the LifEscozul Group, taking into account this situation, decided to increase the dose progressively.
La familia del Sr Eberto reporta que los resultados a nivel médico son óptimos de acuerdo a observación de evolución del paciente y comentarios médicos.
In April 2018, we received new information on PSA where a decrease to 5.83 ng/ml is referred to.
The results of the CT scan of the thorax, abdomen and pelvis, simple and with contrast, showed elimination of mediastinal and cervical adenomegaly.
The presence of bone metastases in C7, T1, T2, T3 and T7, L5, iliac, left iliac, sacrum and right humerus head is maintained.
However, abdomino-pelvic adenomegaly decreased in size.
According to this report, the bone lesions were previously described, and apparently did not present much change, the pelvic, retroperitoneal and right paravesical adenomegalies improved and the mediastinal and cervical adenomegalies disappeared.
All this is indicative of a positive response.
In December 2018 we received a new PSA report: 1.82 ng /ml.
In January 2019 they sent new studies, which showed no significant alterations.
The ultrasound performed did not describe malignant disease, only left renal lithiasis and dilatation of the right urinary tract.
For July 2019 the PSA value reported 1.2ng/ml.
In August 2019 Eberto's daughter writes to us again:
..."Good evening my dear Cuban doctors for me it is a blessing to greet you and tell you this PSA result of my father EBERTO GOMEZ REVOLLO who has been taking the dose for these 2 years since his prostate cancer was discovered.
Let's remember that his PSA was at 2,000 when he started LifEscozul. To the glory of God and your wonderful medicine my father came through this process. Thank you truly for this product and for giving human beings LIFE.
Life that only you and your research can provide.
May God and the Virgin Mary continue to enlighten you"...
June 19, 2020
We received the latest report from Mr. Eberto regarding PSA: 0.28 ng/ml.
No doubt impressive.
For LifEscozul Group, due to our experience and knowledge in case management, it is vital to break the vicious circle that is established between the patient's quality of life and depression.
When Mr. Eberto came to us, we never imagined that we would have such a good result after 2 years of starting LifEscozul (escozul, blue scorpion venom).
His PSA dropped from 2000 ng/ml to 0.20 ng/ml.
His quality of life changed dramatically.
His disease disappeared.
Mr. Eberto has remained stable with no new reports of the disease and with a great attitude as you can see in the interview that our Manager conducted with him a few weeks ago.
We are the LifEscozul Group and the Results Define Us.
Breast cancer is the most common cancer among women and is the second leading cause of death from cancer. View more